Sarah is a Partner and Head of the Life Sciences and Chemistry group at Kilburn & Strode LLP. She specialises in the field of biotechnology, and has significant expertise and experience in the areas of antibody and TCR technology, synthetic biology, next-generation DNA sequencing technologies, proteomics and diagnostics.
With over 20 years’ experience, Sarah is skilled at handling all stages of the patenting process, from the initial stages of invention capture and drafting patent applications through international prosecution to EPO oppositions and appeals. Although she has a wide client base, she particularly enjoys using her formidable strategic and commercial skills to help clients achieve their business aims, whether those are raising further funds, initial public offering or launching a product.
She is renowned for her brilliant client care, with IAM Patent, 2024 noting “She blends a commercially pragmatic approach with a personalised service and tailored solutions, to ensure her patrons come out on top.” IAM Patent, 2025 acknowledged her as "...a fantastic partner, known for her detail-oriented and strategic approach. She has a deep understanding of her clientele and their technologies, making her a critical asset in strategic prosecution across the UK and Europe." Sarah was also recognised as a “standout individual” in the 2023 edition of The Legal 500.
She has a burgeoning practice in technologies where the life sciences intersects with other fields, including bioinformatics and digital health. For such technologies, an interdisciplinary approach is often required, for example when machine learning and AI are used in the life sciences field. Sarah enjoys working together with her colleagues across the firm as part of a truly interdisciplinary team to provide a bespoke experience to clients in these sectors.